August 11, 2025 - 19:09

Tempest has made notable progress in its oncology pipeline, receiving clearance to initiate a pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China. This advancement marks a critical step in the quest to provide effective treatment options for patients battling this aggressive form of liver cancer.
In addition to the trial clearance in China, the company has been granted orphan drug designation by the European Medicines Agency (EMA) for amezalpat, further highlighting the therapy's potential in addressing unmet medical needs for HCC patients. This designation is crucial as it provides various incentives to expedite the development and review of the drug.
At the recent 2025 AACR Annual Meeting, Tempest presented new data on the mechanism of action of amezalpat, reinforcing its promise as a novel cancer treatment. Furthermore, the FDA has granted orphan drug designation for TPST-1495, aimed at treating familial adenomatous polyposis, showcasing the company's commitment to advancing therapies for rare diseases.
November 8, 2026 - 01:44
OUTFRONT Media Reports Strong Q3 Earnings and Raises OutlookOUTFRONT Media reported a notable 9 percent revenue growth for the third quarter of 2026, driven primarily by a surge in transit advertising and increased spending associated with the FIFA World...
November 7, 2026 - 08:13
Definity Financial Corp Reports Strong Premium Growth Despite Weather ChallengesDefinity Financial Corp announced impressive financial results for the third quarter of 2026, showcasing a significant surge in gross written premiums. The company reported $1.7 billion in premiums...
November 6, 2026 - 01:15
David Gilbert Takes on Role as Interim CFO at TransUnionTransUnion has announced the appointment of David Gilbert as its Interim Chief Financial Officer, starting January 1, 2027. This change is part of a planned leadership transition from the current...
November 5, 2026 - 02:21
A New Approach to K-12 School Finance ReformAs the landscape of education continues to evolve, state policymakers are faced with the urgent need for a K-12 finance agenda that emphasizes transparency, sustainability, and productivity. This...